<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099421</url>
  </required_header>
  <id_info>
    <org_study_id>H-17000714-1</org_study_id>
    <nct_id>NCT03099421</nct_id>
  </id_info>
  <brief_title>Prostatic Artery Embolization for Benign Prostatic Obstruction</brief_title>
  <official_title>Prostatic Artery Embolization for Benign Prostatic Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the safety and efficacy of prostatic artery
      embolization (PAE) for patients who refuse or are not eligible for surgery with
      moderate-severe lower urinary tract symptoms or indwelling catheter secondary to benign
      prostate obstruction due to benign prostatic hyperplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study investigating the safety and efficacy of PAE for patients who
      refuse or are not eligible for surgery and who suffers from moderate-severe lower urinary
      tract symptoms or indwelling catheter secondary to benign prostatic obstruction due to benign
      prostatic hyperplasia. It may form the grounding for further research in the shape of a
      larger randomised clinical trial.

      Our hypothesis is that PAE will eliminate the need for indwelling catheter and improve IPSS
      12 months post-procedure.

      1, 3, 6, 9 and 12 months follow-up.

      Main outcome Ability to void after removal of indwelling catheter

      Secondary outcomes DAN-PSS International Prostate Symptom Score (IPSS) Quality of Life (QoL)
      International Index of Erectile Function (IIEF) Prostate volume Peak void flow (Qmax)
      Post-void residual (PVR) Classify complications according to Society of Interventional
      Radiology (SIR) guidelines for reporting Prostate-specific antigen (PSA)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to void spontaneously</measure>
    <time_frame>1 months</time_frame>
    <description>The ability to void after removal of the indwelling catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IPSS</measure>
    <time_frame>1, 3, 6, 9, 12 months</time_frame>
    <description>International Prostate Symptom Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>1, 3, 6, 9, 12 months</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF</measure>
    <time_frame>1, 3, 6, 12 months</time_frame>
    <description>International Index of Erectile Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PV</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Prostate Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PVR</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Post-void residual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qmax</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Peak void flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Prostate-specific antigen</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperplasia Prostatic</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Prostatic Diseases</condition>
  <condition>Urological Manifestations</condition>
  <arm_group>
    <arm_group_label>Prostatic Artery Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostatic Artery Embolization</intervention_name>
    <description>The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.</description>
    <arm_group_label>Prostatic Artery Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indwelling catheter secondary to benign prostatic hyperplasia (BPH) or

          -  Moderate-severe Obstructive LUTS secondary to BPH refractory to medical treatment

          -  Unsuitable for TURP or refuse surgery

        Exclusion Criteria:

          -  Bladder dysfunction(and known neurological conditions affecting bladder function)

          -  Urethral strictures

          -  Bladder neck contracture

          -  Known sphincter anomalies

          -  Big bladder diverticulum or stones

          -  Kidney insufficiency (eGFR &lt; 45)

          -  Coagulation disturbances

          -  Severe atheromatous or tortuosity of arteries

          -  Allergy to contrast medium

          -  Unable to undergo MR imaging

          -  Urological malignancy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars LÃ¶nn, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Radiologisk Klinik, Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Malling, MD</last_name>
    <phone>004535453024</phone>
    <email>brian.malling.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Malling, MD</last_name>
      <phone>004535453024</phone>
      <email>brian.malling.01@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>April 1, 2017</last_update_submitted>
  <last_update_submitted_qc>April 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Brian Malling</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Benign prostatic obstruction</keyword>
  <keyword>benign prostatic enlargement</keyword>
  <keyword>benign prostatic hyperplasia</keyword>
  <keyword>prostatic artery embolization</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>IPSS</keyword>
  <keyword>DAN-PSS</keyword>
  <keyword>Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
    <mesh_term>Urological Manifestations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

